{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T20:22:11Z","timestamp":1789935731465,"version":"4.0.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,7,5]],"date-time":"2017-07-05T00:00:00Z","timestamp":1499212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,7,5]],"date-time":"2017-07-05T00:00:00Z","timestamp":1499212800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Current standard-of-care treatment of chronically infected hepatitis C virus (HCV) patients involves direct-acting antivirals (DAA). However, concerns exist regarding the emergence of drug -resistant variants and subsequent treatment failure. In this study, we investigate potential natural drug-resistance mutations in the NS5B gene of HCV genotype 1b from treatment-na\u00efve patients. Population-based sequencing and 454 deep sequencing of NS5B gene were performed on plasma and liver samples obtained from 18 treatment- na\u00efve patients. The quasispecies distribution in plasma and liver samples showed a remarkable overlap in each patient. Although unique sequences in plasma or liver were observed, in the majority of cases the most dominant sequences were shown to be identical in both compartments. Neither in plasma nor in the liver codon changes were detected at position 282 that cause resistance to nucleos(t)ide analogues. However, in 10 patients the V321I change conferring resistance to nucleos(t)ide NS5B polymerase inhibitors and in 16 patients the C316N\/Y\/H non-nucleoside inhibitors were found mainly in liver samples. In conclusion, 454-deep sequencing of liver and plasma compartments in treatment na\u00efve patients provides insight into viral quasispecies and the pre-existence of some drug-resistant variants in the liver, which are not necessarily present in plasma.<\/jats:p>","DOI":"10.1038\/s41598-017-04931-y","type":"journal-article","created":{"date-parts":[[2017,6,29]],"date-time":"2017-06-29T11:15:40Z","timestamp":1498734940000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Identification of HCV Resistant Variants against Direct Acting Antivirals in Plasma and Liver of Treatment Na\u00efve Patients"],"prefix":"10.1038","volume":"7","author":[{"given":"V. Stalin","family":"Raj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5627-9675","authenticated-orcid":false,"given":"Gadissa Bedada","family":"Hundie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita C.","family":"Sch\u00fcrch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia L.","family":"Smits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzan D.","family":"Pas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Le Pogam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry L. A.","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob J.","family":"de Knegt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert D. M. E.","family":"Osterhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Najera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles A.","family":"Boucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart L.","family":"Haagmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,5]]},"reference":[{"key":"4931_CR1","doi-asserted-by":"publisher","first-page":"3173","DOI":"10.1099\/vir.0.80401-0","volume":"85","author":"P Simmonds","year":"2004","unstructured":"Simmonds, P. Genetic diversity and evolution of hepatitis C virus\u201315 years on. J Gen Virol \n                           85, 3173\u20133188 (2004).","journal-title":"J Gen Virol"},{"key":"4931_CR2","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1002\/hep.20819","volume":"42","author":"P Simmonds","year":"2005","unstructured":"Simmonds, P. et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology \n                           42, 962\u2013973 (2005).","journal-title":"Hepatology"},{"key":"4931_CR3","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1126\/science.282.5386.103","volume":"282","author":"AU Neumann","year":"1998","unstructured":"Neumann, A. U. et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science \n                           282, 103\u2013107 (1998).","journal-title":"Science"},{"key":"4931_CR4","doi-asserted-by":"publisher","first-page":"7569","DOI":"10.1128\/JVI.00312-06","volume":"80","author":"S Noppornpanth","year":"2006","unstructured":"Noppornpanth, S. et al. Identification of a naturally occurring recombinant genotype 2\/6 hepatitis C virus. J Virol \n                           80, 7569\u20137577 (2006).","journal-title":"J Virol"},{"key":"4931_CR5","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.1073\/pnas.88.8.3392","volume":"88","author":"N Ogata","year":"1991","unstructured":"Ogata, N., Alter, H. J., Miller, R. H. & Purcell, R. H. Nucleotide sequence and mutation rate of the H strain of hepatitis C virus. Proc Natl Acad Sci USA \n                           88, 3392\u20133396 (1991).","journal-title":"Proc Natl Acad Sci USA"},{"key":"4931_CR6","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1128\/jvi.66.5.3225-3229.1992","volume":"66","author":"M Martell","year":"1992","unstructured":"Martell, M. et al. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J Virol \n                           66, 3225\u20133229 (1992).","journal-title":"J Virol"},{"key":"4931_CR7","first-page":"261","volume":"299","author":"JM Pawlotsky","year":"2006","unstructured":"Pawlotsky, J. M. Hepatitis C virus population dynamics during infection. Curr Top Microbiol Immunol \n                           299, 261\u2013284 (2006).","journal-title":"Curr Top Microbiol Immunol"},{"key":"4931_CR8","doi-asserted-by":"publisher","first-page":"419","DOI":"10.3748\/wjg.v17.i4.419","volume":"17","author":"A Tsubota","year":"2011","unstructured":"Tsubota, A., Fujise, K., Namiki, Y. & Tada, N. Peginterferon and ribavirin treatment for hepatitis C virus infection. World J Gastroenterol \n                           17, 419\u2013432 (2011).","journal-title":"World J Gastroenterol"},{"key":"4931_CR9","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.jhep.2015.09.011","volume":"64","author":"C Sarrazin","year":"2016","unstructured":"Sarrazin, C. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol \n                           64, 486\u2013504 (2016).","journal-title":"J Hepatol"},{"issue":"Suppl 1","key":"4931_CR10","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1093\/infdis\/jis761","volume":"207","author":"DL Wyles","year":"2013","unstructured":"Wyles, D. L. Antiviral resistance and the future landscape of hepatitis C virus infection therapy. J Infect Dis \n                           207(Suppl 1), S33\u201339 (2013).","journal-title":"J Infect Dis"},{"key":"4931_CR11","first-page":"289","volume":"369","author":"L Delang","year":"2013","unstructured":"Delang, L. et al. Hepatitis C virus-specific directly acting antiviral drugs. Curr Top Microbiol Immunol \n                           369, 289\u2013320 (2013).","journal-title":"Curr Top Microbiol Immunol"},{"key":"4931_CR12","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.1128\/JCM.00838-12","volume":"50","author":"ES Svarovskaia","year":"2012","unstructured":"Svarovskaia, E. S., Martin, R., McHutchison, J. G., Miller, M. D. & Mo, H. Abundant drug-resistant NS3 mutants detected by deep sequencing in hepatitis C virus-infected patients undergoing NS3 protease inhibitor monotherapy. J Clin Microbiol \n                           50, 3267\u20133274 (2012).","journal-title":"J Clin Microbiol"},{"key":"4931_CR13","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1128\/JCM.05842-11","volume":"50","author":"S Fonseca-Coronado","year":"2012","unstructured":"Fonseca-Coronado, S. et al. Specific detection of naturally occurring hepatitis C virus mutants with resistance to telaprevir and boceprevir (protease inhibitors) among treatment-naive infected individuals. J Clin Microbiol \n                           50, 281\u2013287 (2012).","journal-title":"J Clin Microbiol"},{"key":"4931_CR14","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1053\/j.gastro.2012.07.117","volume":"143","author":"O Lenz","year":"2012","unstructured":"Lenz, O. et al. Efficacy of re-treatment with TMC435 as combination therapy in hepatitis C virus-infected patients following TMC435 monotherapy. Gastroenterology \n                           143, 1176\u20131178 (2012).","journal-title":"Gastroenterology"},{"key":"4931_CR15","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1128\/JCM.05715-11","volume":"50","author":"M Ninomiya","year":"2012","unstructured":"Ninomiya, M. et al. Use of illumina deep sequencing technology to differentiate hepatitis C virus variants. J Clin Microbiol \n                           50, 857\u2013866 (2012).","journal-title":"J Clin Microbiol"},{"key":"4931_CR16","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1053\/j.gastro.2007.02.037","volume":"132","author":"C Sarrazin","year":"2007","unstructured":"Sarrazin, C. et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology \n                           132, 1767\u20131777 (2007).","journal-title":"Gastroenterology"},{"key":"4931_CR17","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1002\/hep.23192","volume":"50","author":"S Susser","year":"2009","unstructured":"Susser, S. et al. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology \n                           50, 1709\u20131718 (2009).","journal-title":"Hepatology"},{"key":"4931_CR18","doi-asserted-by":"publisher","first-page":"e11345","DOI":"10.1371\/journal.pone.0011345","volume":"5","author":"C Hedskog","year":"2010","unstructured":"Hedskog, C. et al. Dynamics of HIV-1 quasispecies during antiviral treatment dissected using ultra-deep pyrosequencing. PLoS One \n                           5, e11345 (2010).","journal-title":"PLoS One"},{"key":"4931_CR19","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1086\/596736","volume":"199","author":"BB Simen","year":"2009","unstructured":"Simen, B. B. et al. Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes. J Infect Dis \n                           199, 693\u2013701 (2009).","journal-title":"J Infect Dis"},{"key":"4931_CR20","doi-asserted-by":"publisher","first-page":"4161","DOI":"10.1128\/AAC.00433-06","volume":"50","author":"H Dutartre","year":"2006","unstructured":"Dutartre, H., Bussetta, C., Boretto, J. & Canard, B. General catalytic deficiency of hepatitis C virus RNA polymerase with an S282T mutation and mutually exclusive resistance towards 2\u2032-modified nucleotide analogues. Antimicrob Agents Chemother \n                           50, 4161\u20134169 (2006).","journal-title":"Antimicrob Agents Chemother"},{"key":"4931_CR21","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1128\/AAC.01598-08","volume":"53","author":"MF McCown","year":"2009","unstructured":"McCown, M. F., Rajyaguru, S., Kular, S., Cammack, N. & Najera, I. GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796. Antimicrob Agents Chemother \n                           53, 2129\u20132132 (2009).","journal-title":"Antimicrob Agents Chemother"},{"key":"4931_CR22","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1128\/AAC.00834-07","volume":"52","author":"ST Shi","year":"2008","unstructured":"Shi, S. T. et al. In vitro resistance study of AG-021541, a novel nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase. Antimicrob Agents Chemother \n                           52, 675\u2013683 (2008).","journal-title":"Antimicrob Agents Chemother"},{"key":"4931_CR23","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.jhep.2005.05.032","volume":"43","author":"Y Asahina","year":"2005","unstructured":"Asahina, Y. et al. Mutagenic effects of ribavirin and response to interferon\/ribavirin combination therapy in chronic hepatitis C. J Hepatol \n                           43, 623\u2013629 (2005).","journal-title":"J Hepatol"},{"key":"4931_CR24","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1590\/S0074-02762011000800011","volume":"106","author":"MC Castilho","year":"2011","unstructured":"Castilho, M. C. et al. Association of hepatitis C virus NS5B variants with resistance to new antiviral drugs among untreated patients. Mem Inst Oswaldo Cruz \n                           106, 968\u2013975 (2011).","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"4931_CR25","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1111\/j.1440-1746.2005.04024.x","volume":"20","author":"K Hamano","year":"2005","unstructured":"Hamano, K. et al. Mutations in the NS5B region of the hepatitis C virus genome correlate with clinical outcomes of interferon-alpha plus ribavirin combination therapy. J Gastroenterol Hepatol \n                           20, 1401\u20131409 (2005).","journal-title":"J Gastroenterol Hepatol"},{"key":"4931_CR26","doi-asserted-by":"publisher","first-page":"e1002243","DOI":"10.1371\/journal.ppat.1002243","volume":"7","author":"RA Bull","year":"2011","unstructured":"Bull, R. A. et al. Sequential bottlenecks drive viral evolution in early acute hepatitis C virus infection. PLoS Pathog \n                           7, e1002243 (2011).","journal-title":"PLoS Pathog"},{"key":"4931_CR27","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1126\/science.288.5464.339","volume":"288","author":"P Farci","year":"2000","unstructured":"Farci, P. et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science \n                           288, 339\u2013344 (2000).","journal-title":"Science"},{"key":"4931_CR28","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.1073\/pnas.052712599","volume":"99","author":"P Farci","year":"2002","unstructured":"Farci, P. et al. Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome. Proc Natl Acad Sci USA \n                           99, 3081\u20133086 (2002).","journal-title":"Proc Natl Acad Sci USA"},{"key":"4931_CR29","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1053\/j.gastro.2004.06.005","volume":"127","author":"T Laskus","year":"2004","unstructured":"Laskus, T. et al. Analysis of hepatitis C virus quasispecies transmission and evolution in patients infected through blood transfusion. Gastroenterology \n                           127, 764\u2013776 (2004).","journal-title":"Gastroenterology"},{"key":"4931_CR30","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1128\/jvi.71.2.1732-1734.1997","volume":"71","author":"B Cabot","year":"1997","unstructured":"Cabot, B. et al. Structure of replicating hepatitis C virus (HCV) quasispecies in the liver may not be reflected by analysis of circulating HCV virions. J Virol \n                           71, 1732\u20131734 (1997).","journal-title":"J Virol"},{"key":"4931_CR31","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1055\/s-0031-1297925","volume":"31","author":"P Farci","year":"2011","unstructured":"Farci, P. New insights into the HCV quasispecies and compartmentalization. Semin Liver Dis \n                           31, 356\u2013374 (2011).","journal-title":"Semin Liver Dis"},{"issue":"Pt 7","key":"4931_CR32","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1099\/0022-1317-78-7-1521","volume":"78","author":"F Maggi","year":"1997","unstructured":"Maggi, F. et al. Differences in hepatitis C virus quasispecies composition between liver, peripheral blood mononuclear cells and plasma. J Gen Virol \n                           78(Pt 7), 1521\u20131525 (1997).","journal-title":"J Gen Virol"},{"key":"4931_CR33","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1128\/JVI.72.2.1640-1646.1998","volume":"72","author":"S Navas","year":"1998","unstructured":"Navas, S., Martin, J., Quiroga, J. A., Castillo, I. & Carreno, V. Genetic diversity and tissue compartmentalization of the hepatitis C virus genome in blood mononuclear cells, liver, and serum from chronic hepatitis C patients. J Virol \n                           72, 1640\u20131646 (1998).","journal-title":"J Virol"},{"key":"4931_CR34","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1002\/hep.510290117","volume":"29","author":"M Okuda","year":"1999","unstructured":"Okuda, M. et al. Differences in hypervariable region 1 quasispecies of hepatitis C virus in human serum, peripheral blood mononuclear cells, and liver. Hepatology \n                           29, 217\u2013222 (1999).","journal-title":"Hepatology"},{"key":"4931_CR35","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1002\/hep.22773","volume":"49","author":"S Gaudieri","year":"2009","unstructured":"Gaudieri, S. et al. Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy. Hepatology \n                           49, 1069\u20131082 (2009).","journal-title":"Hepatology"},{"key":"4931_CR36","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/j.1600-6143.2011.03854.x","volume":"12","author":"EJ Gane","year":"2012","unstructured":"Gane, E. J. Diabetes mellitus following liver transplantation in patients with hepatitis C virus: risks and consequences. Am J Transplant \n                           12, 531\u2013538 (2012).","journal-title":"Am J Transplant"},{"key":"4931_CR37","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1128\/AAC.49.5.2059-2069.2005","volume":"49","author":"SW Ludmerer","year":"2005","unstructured":"Ludmerer, S. W. et al. Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay. Antimicrob Agents Chemother \n                           49, 2059\u20132069 (2005).","journal-title":"Antimicrob Agents Chemother"},{"key":"4931_CR38","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.jcv.2013.09.022","volume":"58","author":"S Franco","year":"2013","unstructured":"Franco, S. et al. No detection of the NS5B S282T mutation in treatment-naive genotype 1 HCV\/HIV-1 coinfected patients using deep sequencing. J Clin Virol \n                           58, 726\u2013729 (2013).","journal-title":"J Clin Virol"},{"key":"4931_CR39","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1128\/AAC.02386-13","volume":"58","author":"VC Di Maio","year":"2014","unstructured":"Di Maio, V. C. et al. Hepatitis C virus genetic variability and the presence of NS5B resistance-associated mutations as natural polymorphisms in selected genotypes could affect the response to NS5B inhibitors. Antimicrob Agents Chemother \n                           58, 2781\u20132797 (2014).","journal-title":"Antimicrob Agents Chemother"},{"key":"4931_CR40","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1053\/j.gastro.2009.11.055","volume":"138","author":"C Sarrazin","year":"2010","unstructured":"Sarrazin, C. & Zeuzem, S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology \n                           138, 447\u2013462 (2010).","journal-title":"Gastroenterology"},{"key":"4931_CR41","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1128\/JVI.02294-12","volume":"87","author":"DJ Bartels","year":"2013","unstructured":"Bartels, D. J. et al. Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment. J Virol \n                           87, 1544\u20131553 (2013).","journal-title":"J Virol"},{"key":"4931_CR42","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1093\/jac\/dkp328","volume":"64","author":"PD Dryer","year":"2009","unstructured":"Dryer, P. D. et al. Screening for hepatitis C virus non-nucleotide resistance mutations in treatment-naive women. J Antimicrob Chemother \n                           64, 945\u2013948 (2009).","journal-title":"J Antimicrob Chemother"},{"key":"4931_CR43","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1093\/jac\/dkn085","volume":"61","author":"S Le Pogam","year":"2008","unstructured":"Le Pogam, S. et al. Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients. J Antimicrob Chemother \n                           61, 1205\u20131216 (2008).","journal-title":"J Antimicrob Chemother"},{"key":"4931_CR44","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S0166-0934(03)00070-3","volume":"109","author":"K Sandres-Saune","year":"2003","unstructured":"Sandres-Saune, K. et al. Determining hepatitis C genotype by analyzing the sequence of the NS5b region. J Virol Methods \n                           109, 187\u2013193 (2003).","journal-title":"J Virol Methods"},{"key":"4931_CR45","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1093\/molbev\/msr121","volume":"28","author":"K Tamura","year":"2011","unstructured":"Tamura, K. et al. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol \n                           28, 2731\u20132739 (2011).","journal-title":"Mol Biol Evol"},{"key":"4931_CR46","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1093\/bioinformatics\/btp163","volume":"25","author":"PJ Cock","year":"2009","unstructured":"Cock, P. J. et al. Biopython: freely available Python tools for computational molecular biology and bioinformatics. Bioinformatics \n                           25, 1422\u20131423 (2009).","journal-title":"Bioinformatics"},{"key":"4931_CR47","doi-asserted-by":"publisher","first-page":"e1002529","DOI":"10.1371\/journal.ppat.1002529","volume":"8","author":"MR Henn","year":"2012","unstructured":"Henn, M. R. et al. Whole genome deep sequencing of HIV-1 reveals the impact of early minor variants upon immune recognition during acute infection. PLoS Pathog \n                           8, e1002529 (2012).","journal-title":"PLoS Pathog"},{"key":"4931_CR48","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1101\/gr.070227.107","volume":"18","author":"W Brockman","year":"2008","unstructured":"Brockman, W. et al. Quality scores and SNP detection in sequencing-by-synthesis systems. Genome Res \n                           18, 763\u2013770 (2008).","journal-title":"Genome Res"},{"key":"4931_CR49","doi-asserted-by":"publisher","first-page":"e1002417","DOI":"10.1371\/journal.pcbi.1002417","volume":"8","author":"AR Macalalad","year":"2012","unstructured":"Macalalad, A. R. et al. Highly sensitive and specific detection of rare variants in mixed viral populations from massively parallel sequence data. PLoS Comput Biol \n                           8, e1002417 (2012).","journal-title":"PLoS Comput Biol"},{"key":"4931_CR50","unstructured":"Holtgrewe, M. Mason \u2013 a read simulator for second generation sequencingdata. http:\/\/publications.mi.fu-berlin.de\/962\/ (FU Berlin, 2010)."},{"key":"4931_CR51","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/163688a0","volume":"163","author":"EH Simpson","year":"1949","unstructured":"Simpson, E. H. Measurement of diversity. Nature \n                           163, 688 (1949).","journal-title":"Nature"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-04931-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-04931-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-04931-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T06:07:49Z","timestamp":1671775669000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-04931-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,5]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["4931"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-04931-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,5]]},"assertion":[{"value":"15 March 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. A.D.M.E. Osterhaus and Dr. S.L. Smits are part time chief scientific officer and senior scientist respectively of Viroclinics Biosciences B.V. Dr. H.L.A. Janssen received grants from and is a consultant for: Bristol Myers Squibb, Gilead Sciences, Novartis, InnoGenetics, Roche and Merck. Dr. C.A.B. Boucher received grants from and is consultant for Merck, Roche and Abvie.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"4688"}}